Dexcom G7

An advanced CGM with insulin pump connectivity 
and predictive alerts 

Image
Powerfully Simple Glucose Monitoring

Most Connected 
CGM 


The worlds most connected CGM* making it seamless to manage diabetes across various smart devices, health apps, and insulin delivery devices, including the t:slim X2 insulin pump. 

Advanced CGM with 
predictive alerts 


Dexcom G7 offers advanced alert settings 
including the predictive Urgent Low Soon alert and the 
new Silence All or vibrate modes, for added discretion and personalisation3

Other features of Dexcom G7

Easy for you

 

Self-start CGM for your patients1  Dexcom Clarity integration for simple pattern analysis and actionable insights Your patients can share their 
glucose data with you directly from the Dexcom Clarity App

Easy for your patients 

 

All in one wearable with simple insertion and self-setup in app1

Along with Dexcom ONE+, Dexcom G7 is the smallest sensor in Australia2

Along with Dexcom ONE+, Dexcom G7 has a 30-minute warm up sensor time - the fastest of any CGM on the market§10-day sensor wear with an additional 12-hour grace period, making changing sensors more convenient.
Optional Dexcom G7 Share/Follow 
feature offers patients the 
opportunity to share their glucose data with support network for added peace of mind and support4
    

Superior Accuracy||


Dexcom G7, alongside Dexcom ONE+, is our most accurate CGM System, giving people the confidence to make 
informed decisions. ||,4
 

  • 8.2% overall adult MARD (back of the arm)5
  • 8.1% overall paediatric MARD (back of the arm)6
  • 95.3% repeatable precision in both adults and children5

 

Better Health Outcomes4,7-10

 

Dexcom G7 can help avoid hypoglycaemia (with Urgent Low Soon Alert) and rebound hyperglycaemia, enabling immediate action.¶,11,12 

  • Most researched CGM with over 250 registered clinical trials13
  • Can reduce HbAIC by 1%11
  • Can reduce hypoglycaemia by 40%11
  • Increase time in range by 11.2% for MDI users14
  • Increase time in range by 14.5% for CSII users14
  • Improve overall wellbeing and quality of life15

Dexcom G7 Components

All-in-one Sensor

All-in-one Sensor

Measures interstitial glucose levels for up 
to 10 days, with a 12-hour grace period.

The 24.1 mm height makes our sensor the 
smallest on the market!14

One-push Applicator

One-push Applicator

Inserts the sensor. Its clever design 
means the user only has to push 
one button to get started.

Display Device

Display Device

Smartphone with Dexcom G7 app or 
optional receiver displays readings in real-time.†,#

Display devices sold separately and connected Smart device required to display readings on watch.


 

Want to learn more 
about Dexcom G7?

Dexcom offers simplified healthcare professional (HCP) 
education, resources and support through our Education Hub.

VISIT THE AMSL EDUCATION HUB    

Dexcom G7

 

Get in touch with a Dexcom Representative today!

 

    CONTACT US    

 

 

References:

*Not all connections are available in Australia. To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/compatibility
†Smart devices sold separately. For a list of compatible devices, visit www.dexcom.com/compatibility
‡Internet connection required to send data to Dexcom Clarity. 
§ Dexcom G7 and ONE+ can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
|| As compared to Dexcom G6
¶ Based on a study of 1,424 real-world users
# A receiver can be acquired as an optional display device.

1. Dexcom ONE+ System User Guide 
2. Dexcom G7 User Guide, Dexcom ONE+ User Guide, Freestyle Libre 2 User Manual, Medtronic Guardian 4 Instructions for Use
3. Dexcom G7 User Guide 
4. Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7
5. Garg SK, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022;24(6):373-8045
6. Laffel LM et al. J Diabetes Sci Technol. 2023 Jul; 17(4): 962–967.
7. Beck RW, et al. JAMA. 2017;317(4):371-378; 
8. Beck RW, et al. Ann Intern Med. 2017;167(6):365-374; 
9. Martens T, et al. JAMA. 2021;325(22):2262-2272; 
10. Laffel LM, et al. JAMA. 2020;323(23):2388-2396; 
11. Puhr S, et al. Diabetes Technol Ther. 2019 Apr;21(4):155-158​
12. Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677-82
13. clinicaltrials.gov
14. Šoupal J, et al. Diabetes Care. 2020;43:37-43
15. Lind M, et al. JAMA. 2017;317(4):37987;